Literature DB >> 31785786

Integrating Clinical Data and Imputed Transcriptome from GWAS to Uncover Complex Disease Subtypes: Applications in Psychiatry and Cardiology.

Liangying Yin1, Carlos K L Chau1, Pak-Chung Sham2, Hon-Cheong So3.   

Abstract

Classifying subjects into clinically and biologically homogeneous subgroups will facilitate the understanding of disease pathophysiology and development of targeted prevention and intervention strategies. Traditionally, disease subtyping is based on clinical characteristics alone, but subtypes identified by such an approach may not conform exactly to the underlying biological mechanisms. Very few studies have integrated genomic profiles (e.g., those from GWASs) with clinical symptoms for disease subtyping. Here we proposed an analytic framework capable of finding complex diseases subgroups by leveraging both GWAS-predicted gene expression levels and clinical data by a multi-view bicluster analysis. This approach connects SNPs to genes via their effects on expression, so the analysis is more biologically relevant and interpretable than a pure SNP-based analysis. Transcriptome of different tissues can also be readily modeled. We also proposed various evaluation metrics for assessing clustering performance. Our framework was able to subtype schizophrenia subjects into diverse subgroups with different prognosis and treatment response. We also applied the framework to the Northern Finland Birth Cohort (NFBC) 1966 dataset and identified high and low cardiometabolic risk subgroups in a gender-stratified analysis. The prediction strength by cross-validation was generally greater than 80%, suggesting good stability of the clustering model. Our results suggest a more data-driven and biologically informed approach to defining metabolic syndrome and subtyping psychiatric disorders. Moreover, we found that the genes "blindly" selected by the algorithm are significantly enriched for known susceptibility genes discovered in GWASs of schizophrenia or cardiovascular diseases. The proposed framework opens up an approach to subject stratification.
Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; clustering; disease subtyping; gene expression; genome-wide association study; schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 31785786      PMCID: PMC6904812          DOI: 10.1016/j.ajhg.2019.10.012

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  75 in total

1.  MissForest--non-parametric missing value imputation for mixed-type data.

Authors:  Daniel J Stekhoven; Peter Bühlmann
Journal:  Bioinformatics       Date:  2011-10-28       Impact factor: 6.937

Review 2.  Gender aspects in schizophrenia: bridging the border between social and biological psychiatry.

Authors:  A Riecher-Rössler; H Häfner
Journal:  Acta Psychiatr Scand Suppl       Date:  2000

Review 3.  Impaired DNA damage repair as a common feature of neurodegenerative diseases and psychiatric disorders.

Authors:  H Shiwaku; H Okazawa
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

4.  Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies.

Authors:  Javier Arnedo; Dragan M Svrakic; Coral Del Val; Rocío Romero-Zaliz; Helena Hernández-Cuervo; Ayman H Fanous; Michele T Pato; Carlos N Pato; Gabriel A de Erausquin; C Robert Cloninger; Igor Zwir
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

5.  Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans.

Authors: 
Journal:  Science       Date:  2015-05-07       Impact factor: 47.728

Review 6.  10 Years of GWAS Discovery: Biology, Function, and Translation.

Authors:  Peter M Visscher; Naomi R Wray; Qian Zhang; Pamela Sklar; Mark I McCarthy; Matthew A Brown; Jian Yang
Journal:  Am J Hum Genet       Date:  2017-07-06       Impact factor: 11.025

Review 7.  Metabolic syndrome: definitions and controversies.

Authors:  Eva Kassi; Panagiota Pervanidou; Gregory Kaltsas; George Chrousos
Journal:  BMC Med       Date:  2011-05-05       Impact factor: 8.775

8.  Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.

Authors:  T Lencz; A K Malhotra
Journal:  Mol Psychiatry       Date:  2015-04-14       Impact factor: 15.992

9.  Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review.

Authors:  Susana Ochoa; Judith Usall; Jesús Cobo; Xavier Labad; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-04-08

Review 10.  Gender differences in cardiovascular disease and comorbid depression.

Authors:  Anne Maria Möller-Leimkühler
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more
  4 in total

Review 1.  Approaches to Defining Common and Dissociable Neurobiological Deficits Associated With Psychopathology in Youth.

Authors:  Antonia N Kaczkurkin; Tyler M Moore; Aristeidis Sotiras; Cedric Huchuan Xia; Russell T Shinohara; Theodore D Satterthwaite
Journal:  Biol Psychiatry       Date:  2019-12-23       Impact factor: 13.382

2.  Prioritization of schizophrenia risk genes from GWAS results by integrating multi-omics data.

Authors:  Dan He; Cong Fan; Mengling Qi; Yuedong Yang; David N Cooper; Huiying Zhao
Journal:  Transl Psychiatry       Date:  2021-03-17       Impact factor: 6.222

3.  Leveraging eQTLs to identify individual-level tissue of interest for a complex trait.

Authors:  Arunabha Majumdar; Claudia Giambartolomei; Na Cai; Tanushree Haldar; Tommer Schwarz; Michael Gandal; Jonathan Flint; Bogdan Pasaniuc
Journal:  PLoS Comput Biol       Date:  2021-05-21       Impact factor: 4.779

Review 4.  Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction.

Authors:  Fanglin Guan; Tong Ni; Weili Zhu; L Keoki Williams; Long-Biao Cui; Ming Li; Justin Tubbs; Pak-Chung Sham; Hongsheng Gui
Journal:  Mol Psychiatry       Date:  2021-06-30       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.